Table 7.
RCC patients with different circKCNK2 expression underwent denosumab treatment.
| Patient ID | Age | Sex | Bone metastatic site | Denosumab Therapy (Months) | Histological Type | Response | CircKCNK2 expression |
|---|---|---|---|---|---|---|---|
| RBM-1 | 70 | F | Rib (left) | 6 | ccRCC | PD | High |
| RBM-2 | 58 | M | Pelvis | 6 | ccRCC | PR | Low |
| RBM-3 | 59 | M | Pelvis | 5 | ccRCC | SD | Low |
| RBM-4 | 72 | M | Rib (right) | 8 | ccRCC | SD | High |
| RBM-5 | 65 | M | Multiple sites | 6 | ccRCC | SD | High |
| RBM-6 | 66 | M | Pelvis | 5 | ccRCC | PD | High |
| RBM-7 | 59 | F | Pelvis | 8 | ccRCC | SD | Low |
| RBM-8 | 79 | M | Thoracic vertebra | 10 | ccRCC | SD | Low |
| RBM-9 | 81 | M | Rib (right) | 4 | ccRCC | PD | Low |
| RBM-10 | 60 | F | Rib (leift) | 6 | ccRCC | PR | Low |
| RBM-11 | 59 | M | Lumber vertebra | 15 | ccRCC | PD | High |
| RBM-12 | 66 | F | Lumber vertebra | 12 | ccRCC | SD | High |
F Female, M Male, RBM RCC bone metastasis, PD Progression disease, PR Partial Response, SD Stable disease.